
Surmodics SRDX
Quarterly report 2025-Q2
added 08-08-2025
Surmodics Total Assets 2011-2026 | SRDX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 179 M | 186 M | 158 M | 195 M | 169 M | 160 M | 164 M | 137 M | 133 M | 98.7 M | 105 M | 102 M | 103 M | 163 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 98.7 M | 146 M |
Quarterly Total Assets Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 M | 163 M | 164 M | 179 M | 177 M | 183 M | 180 M | 186 M | 189 M | 166 M | 170 M | 158 M | - | 184 M | 185 M | 195 M | 177 M | 195 M | 164 M | 169 M | 169 M | 169 M | 155 M | 160 M | 160 M | 160 M | 151 M | 164 M | 164 M | 164 M | 135 M | 137 M | 137 M | 137 M | 129 M | 133 M | 133 M | 133 M | 112 M | 98.7 M | 98.7 M | 98.7 M | 87.1 M | 105 M | 105 M | 105 M | 95.1 M | 102 M | 102 M | 102 M | 108 M | 104 M | 104 M | 103 M | 152 M | 157 M | 157 M | 157 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 87.1 M | 145 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
10.7 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.2 | -0.61 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Biodesix
BDSX
|
97.2 M | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
BioNano Genomics
BNGO
|
73.6 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
DarioHealth Corp.
DRIO
|
110 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
6.34 B | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Celcuity
CELC
|
467 M | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.82 | 2.31 % | $ 509 M | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.02 | 0.17 % | $ 22 B | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Guardant Health
GH
|
2.01 B | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
IDEXX Laboratories
IDXX
|
3.35 B | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
IQVIA Holdings
IQV
|
29.9 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Illumina
ILMN
|
6.3 B | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 27.11 | -0.66 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Sotera Health Company
SHC
|
3.26 B | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
Mettler-Toledo International
MTD
|
3.71 B | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
CareDx, Inc
CDNA
|
413 M | $ 18.31 | 2.46 % | $ 976 M | ||
|
National Research Corporation
NRC
|
135 M | $ 17.16 | -1.04 % | $ 384 M |